Evidence map›Paper›PMID 42357569›Full record

ArticleMolecules (Basel, Switzerland)2026

An Ultrasensitive Label-Free Aptasensor for Insulin Detection Assisted by Exonuclease III and 2-Aminopurine.

Dongdong Shi, Yanhua He, Guiqin Yan

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Dongdong ShiSchool of Chemistry and Chemical Engineering, Shanxi Normal University, Taiyuan 030031, China.
Yanhua HeSchool of Food Science, Shanxi Normal University, Taiyuan 030031, China.
Guiqin YanSchool of Life Sciences, Shanxi Normal University, Taiyuan 030031, China.

Funding

National Natural Science Foundation of China 31700862
6 · The paper itself

Abstract

We designed a label-free fluorescent aptasensor assisted by exonuclease III (Exo III) for sensitive insulin (Ins) detection. The method has high sensitivity, anti-interference properties and repeatability. Additionally, the label-free fluorescent aptasensor assisted by Exo III used to detect Ins has not been reported on yet. In this study, we connected a modified DNA sequence to the 5' end of an aptamer, modifying it into a hairpin structure and exposing 11 nucleotides at the 3' end containing the base adenine (A). The A was substituted with base 2-aminopurine (2AP) to provide a label-free stable hairpin fluorescent probe (2AP-hairpin probe). This strategy took advantage of the high binding affinity of the Ins aptamer and the susceptibility of 2AP to the local base stacking environment. When Ins is added to the detection system, the 2AP-hairpin probe binds to Ins, adopts a folded state, and blocks Exo III's access to the binding site for cutting DNA. 2AP cannot be released, and the fluorescence of the 2AP-hairpin probe/cDNA/Ins/Exo III system cannot be restored. Ins detection is achieved by comparing changes in the fluorescent intensity before and after adding Ins to the detection system. The detection limit of the aptasensor is as low as 1.62 nM with a linear range of 3-130 nM. Furthermore, it is able to selectively and directly detect Ins in biological fluids, demonstrating significant clinical application value and research significance.

Indexed as

2-AminopurineAptamers, NucleotideBiosensing TechniquesExodeoxyribonucleasesInsulinFluorescent DyesHumans2-AminopurineAptamers, Nucleotideexodeoxyribonuclease IIIExodeoxyribonucleasesFluorescent DyesInsulin2APaptasensorexonuclease IIIfluorescenceinsulinlabel-free

Identifiers

PMID42357569
PMCPMC13304847

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.